Currently, there is not a single standard of care for patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). Pirosa and colleagues present results of a phase II trial to investigate efficacy and safety of a full oral combination of clarithromycin plus lenalidomide in R/R MZL. They found that this treatment was moderately active, with a favorable safety profile and efficacy analogous to that reported for other approved oral drugs.

Inherited erythrocytosis can depends by the dysregulation of the hypoxia pathway and consequent high level of EPO production. Karaghiannis and colleagues performed combined in silico, segregation and functional studies of a European collection of 41 patients and 28 relatives with erythrocytosis with variants of EPAS1, that encodes the hypoxia-inducible factor-2 α (HIF-2α), a major player in the hypoxia pathway. The aim was to determine the causal role of genetic variants, and identify potential candidates eligible for the new HIF-2α inhibitor treatment. Altogether, their study allows accurate clinical follow-up of patients and opens the possibility of a HIF-2α inhibitor treatment, the only targeted treatment in hypoxia-related erythrocytosis.